Rinaldi, Anthony
Pfizer (United States)
2 papers on CoChat
Most cited papers
- Verified
ACC inhibitor alone or co-administered with a DGAT2 inhibitor in patients with non-alcoholic fatty liver disease: two parallel, placebo-controlled, randomized phase 2a trials
Calle, R. A., Amin, N. B., Carvajal-Gonzalez, S., Ross, T. T., Bergman, A., Aggarwal, S., Crowley, C., Rinaldi, A., Mancuso, J., Aggarwal, N., et al. (2021) · Nature Medicine
Liver Disease Diagnosis and TreatmentLipid metabolism and disorders
Cited by 219
- Verified
Acetyl-CoA Carboxylase Inhibition Improves Multiple Dimensions of NASH Pathogenesis in Model Systems
Ross, T. T., Crowley, C., Kelly, K. L., Rinaldi, A., Beebe, D. A., Lech, M. P., Martinez, R. V., Carvajal-Gonzalez, S., Boucher, M., Hirenallur-Shanthappa, D., et al. (2020) · Cellular and Molecular Gastroenterology and Hepatology
Liver Disease Diagnosis and TreatmentLiver physiology and pathology
Cited by 94
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free